Dare Bioscience, Inc. reported that it has raised approximately $16.5 million through its equity offering program as of July 18, 2025, allowing it to potentially regain compliance with Nasdaq's minimum stockholders' equity requirement of $2.5 million. The company has been non-compliant since August 2024, and it will notify Nasdaq for their determination on compliance.